A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...

Researchers at Karolinska Institutet and the Astrid Lindgren Children's Hospital in Sweden have determined how children's ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,295 ...

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

The drugs treat prostate, breast and blood cancers. About 80,000 people with Medicare Part D coverage used them in a one-year ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...